Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.
about
Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast CancerThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceThe p53-estrogen receptor loop in cancerCyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivoPhytoestrogens and breast cancer prevention: possible mechanisms of actionERbeta in breast cancer--onlooker, passive player, or active protector?siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer.Heat shock protein90 in lobular neoplasia of the breast.Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell linesGenome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFRIndole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop.Gonadotropin-positive pituitary tumors accompanied by ovarian tumors in aging female ERbeta-/- mice.Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis.Progesterone--promoter or inhibitor of breast cancer.Differential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog.ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancerLobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapyEstrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention.Estrogen receptor β ligands: recent advances and biomedical applications.Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer.Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer.Divide and Conquer May Not Be the Optimal Approach to Retain the Desirable Estrogenic Attributes of the Cyclopia Nutraceutical Extract, SM6Met.Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.ERβ expression and breast cancer risk prediction for women with atypias.Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.Short-time QiBaoMeiRan Formula Treatment Exerts Estrogenic Activities without Side Effects on Reproductive Tissues in Immature MiceEstrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancerBisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cellsWild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancersIntermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers.A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody.The cervical malignant cells display a down regulation of ER-α but retain the ER-β expressionMechanisms enforcing the estrogen receptor β selectivity of botanical estrogens.Prognostic value of molecular markers and cytogenetic alterations that characterize breast cancer precursor lesions (Review)
P2860
Q26738987-9BA1C1B3-191D-4F20-9371-32F42E1B532EQ26830744-1E482BD4-79C4-43DA-9650-71B897F72D1BQ27027865-4DE4CB64-BB5F-45C9-A630-07C728329775Q27302901-D23A8BE1-502B-42FC-8D94-3D688C814FD7Q28276620-EE73BAD8-0C98-49FA-82B5-FF1966A57F5DQ30438399-F19F4A5F-8EE4-48C3-9002-F34F7BDC1FAAQ31028906-42200489-7583-43AA-9153-B104C1B52E45Q33379951-DD98CF3F-DE9E-4834-A954-C9BA68368906Q33403066-D6819EF2-2492-4C6E-99E5-6AD689132229Q33576510-001FFA5E-24DE-4297-8E3A-C90166EFE020Q33739387-480C2078-55B0-4A93-BAA3-0EE9E2B4247CQ33761468-614F32AA-79C1-423C-8B8E-0C9EB286B9D6Q33778664-17AAC7F5-7278-4B5C-910F-D685F6E0ADBBQ33864656-6BC77B9A-D435-470A-B34E-29BDC6541F74Q34323606-2BD48A35-9C69-4828-9AB5-9E98F359A65FQ34332592-28C18B84-F6CF-485C-BFCA-021F82878F4EQ34334131-CE7BC616-D075-43C9-AAFB-F67561DD27DCQ34537257-04F856B3-013E-4E97-BABA-8EBE5E940B63Q34663257-ADDBDC21-66BC-4847-B909-CEC884D99419Q34736986-B6422F06-A143-42E5-BFFD-D3AE4AE83081Q34972318-A7146925-2EDE-4046-82D3-DD359E0A799AQ35016384-705262FA-C8BC-4A57-9E59-CE4B512A9A8FQ35050479-8C47313E-4227-4CBC-9D0F-7FD3A86A39FDQ35479067-CD15C2EF-95D5-4264-9836-92B5E1D302E0Q35624196-8D33C48C-AF21-4354-9F9D-0AF6829C254AQ35712301-8D5866B8-0A8F-4E32-B261-FB9F23F5659FQ35846896-C297986F-0523-44F9-A08A-097C70A7A2F6Q36248899-05DA9FF1-1096-4807-AB9A-E0D2A79335BFQ36301166-3F269251-43A6-435A-B229-0119DDA59ACAQ36353581-E90360EE-427B-452F-98CD-C3722A629E39Q36582378-1335734B-16B6-446D-83B9-D61534FF17F8Q36636359-E5FE5275-2628-4758-80E5-3E6CABCB292FQ36695878-5E640C28-0987-4398-BB8B-43477298F211Q36999937-EFED25CC-7542-4772-9B10-10971D989363Q37038621-DDEAEBCC-36C1-4B56-8F1E-0B65D9BFEFC2Q37046414-184F4010-F702-4DD5-B0C7-20D70667C7C6Q37049590-70DDC12A-67A5-424B-B3E8-2CEAC893F8EBQ37054568-866234CD-0383-4878-A774-80400F6435D2Q37245953-77C7398E-38A5-4E8C-A02D-6FDFAEB55721Q37269644-E0FF1C2B-0356-4D62-9A0E-01066A11135F
P2860
Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Declining estrogen receptor-be ...... ion of human breast neoplasia.
@en
type
label
Declining estrogen receptor-be ...... ion of human breast neoplasia.
@en
prefLabel
Declining estrogen receptor-be ...... ion of human breast neoplasia.
@en
P2093
P1476
Declining estrogen receptor-be ...... sion of human breast neoplasia
@en
P2093
Christopher R West
Christopher S Foster
Paul H Smith
Penny A O'Neill
Ross Sibson
P304
P356
10.1097/00000478-200312000-00002
P407
P577
2003-12-01T00:00:00Z